Uploaded August 2025 | Updated September 2026, 2 weeks ago
Tags: Microbial Cannabis Testing, Product Safety, Product Quality, Accreditation, Cannabis Testing, Cannabis Regulations, Cannabis Laboratories
Moderator: Sherman, Hom, PhD (@medicinal.genomics)
Panelists: Heather Krug, M.S. (@CDPHE-NPS) , Morgan Keefer (@a2la526 ), Darryll Barkhouse (@bioMérieuxTV), Kristofer Marsh, PhD (@SmithersGroup), Rafael Bombonato (@Curaleaf)
This panel explores critical challenges and opportunities in cannabis testing, focusing on accreditation, standards, allowable methods, and batch size regulations. Industry experts will discuss ways to strengthen testing accuracy, ensure quality control, and improve consumer safety by addressing the variability in testing results, batch size inconsistencies, and the current proficiency testing requirements. The conversation will also tackle potential reforms such as implementing Limits of Detection (LOD) in microbial assays, refining accreditation and proficiency standards, and harmonizing sample collection processes across jurisdictions.
Key Discussion Points:
⦾ Opportunities and challenges with current accreditation processes, validation vs. verification requirements, and allowable methods
⦾ Impact of varying batch size requirements and sample collection practices on testing consistency and reliability
⦾ Exploring the feasibility of adopting LOD-based detection standards for microbial assays
⦾ Addressing issues with Proficiency Testing (PT) samples and requirements to better reflect real-world testing conditions
⦾ Potential reforms in lab accreditation, action levels, and batch size regulations for improved standardization
0:00 - Enhancing Cannabis Testing Standards: An Introduction
0:44 - Panelist Introductions
4:56 - How Batch Size Affects Testing Consistency
7:45 - The Benefits of Standardizing Batch Size and Sampling
10:34 - Why Consistency in Sample Collection is Crucial
12:16 - Addressing Gaps in Current Testing Methods to Improve Accuracy
14:44 - The Challenges of Method Validation and Verification
18:12 - The Importance of LODs in Microbial Assays
20:49 - Factors for Implementing LOD-Based Detection
22:56 - Challenges in Proficiency Testing
28:48 - Reforming PT Samples for Real-World Challenges
31:52 - Needed Reforms for Lab Accreditation
36:04 - Standardizing Batch Size Regulations
37:25 - Aligning Test Levels with the Latest Science
39:48 - The 60-Second Challenge: Standardizing One Testing Requirement
46:13 - Q&A
1:01:55 - Conclusion
Learn More about CannMed: cannmedevents.com
Sign Up for Our Newsletter: share.hsforms.com/1oi57oJDnRN-Uqqc9YPByRA20xr2
The CannMed 25 Innovation & Investment Summit showcased its first international venue, the Wyndham Grand Rio Mar Golf & Beach Resort in Puerto Rico from June 17 - 20, 2025. Since its inception at Harvard Medical School in 2016, CannMed has earned a reputation as the premier destination for cutting-edge research, emerging technologies, and investment opportunities. CannMed 25 continues this tradition with medicinal plant researchers, clinicians and venture capitalists who view this Summit as the industry’s number one showcase for the latest advances in plant-based science, medicine, cultivation, and safety.
Tags: Microbial Cannabis Testing, Product Safety, Product Quality, Accreditation, Cannabis Testing, Cannabis Regulations, Cannabis Laboratories
Moderator: Sherman, Hom, PhD (@medicinal.genomics)
Panelists: Heather Krug, M.S. (@CDPHE-NPS) , Morgan Keefer (@a2la526 ), Darryll Barkhouse (@bioMérieuxTV), Kristofer Marsh, PhD (@SmithersGroup), Rafael Bombonato (@Curaleaf)
This panel explores critical challenges and opportunities in cannabis testing, focusing on accreditation, standards, allowable methods, and batch size regulations. Industry experts will discuss ways to strengthen testing accuracy, ensure quality control, and improve consumer safety by addressing the variability in testing results, batch size inconsistencies, and the current proficiency testing requirements. The conversation will also tackle potential reforms such as implementing Limits of Detection (LOD) in microbial assays, refining accreditation and proficiency standards, and harmonizing sample collection processes across jurisdictions.
Key Discussion Points:
⦾ Opportunities and challenges with current accreditation processes, validation vs. verification requirements, and allowable methods
⦾ Impact of varying batch size requirements and sample collection practices on testing consistency and reliability
⦾ Exploring the feasibility of adopting LOD-based detection standards for microbial assays
⦾ Addressing issues with Proficiency Testing (PT) samples and requirements to better reflect real-world testing conditions
⦾ Potential reforms in lab accreditation, action levels, and batch size regulations for improved standardization
0:00 - Enhancing Cannabis Testing Standards: An Introduction
0:44 - Panelist Introductions
4:56 - How Batch Size Affects Testing Consistency
7:45 - The Benefits of Standardizing Batch Size and Sampling
10:34 - Why Consistency in Sample Collection is Crucial
12:16 - Addressing Gaps in Current Testing Methods to Improve Accuracy
14:44 - The Challenges of Method Validation and Verification
18:12 - The Importance of LODs in Microbial Assays
20:49 - Factors for Implementing LOD-Based Detection
22:56 - Challenges in Proficiency Testing
28:48 - Reforming PT Samples for Real-World Challenges
31:52 - Needed Reforms for Lab Accreditation
36:04 - Standardizing Batch Size Regulations
37:25 - Aligning Test Levels with the Latest Science
39:48 - The 60-Second Challenge: Standardizing One Testing Requirement
46:13 - Q&A
1:01:55 - Conclusion
Learn More about CannMed: cannmedevents.com
Sign Up for Our Newsletter: share.hsforms.com/1oi57oJDnRN-Uqqc9YPByRA20xr2
The CannMed 25 Innovation & Investment Summit showcased its first international venue, the Wyndham Grand Rio Mar Golf & Beach Resort in Puerto Rico from June 17 - 20, 2025. Since its inception at Harvard Medical School in 2016, CannMed has earned a reputation as the premier destination for cutting-edge research, emerging technologies, and investment opportunities. CannMed 25 continues this tradition with medicinal plant researchers, clinicians and venture capitalists who view this Summit as the industry’s number one showcase for the latest advances in plant-based science, medicine, cultivation, and safety.
